Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
Jordan
V C
VC
D000818:Animals; D001943:Breast Neoplasms / Q000378:metabolism / Q000517:prevention & control*; D019008:Drug Resistance, Neoplasm; D004965:Estrogen Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D004967:Estrogens / Q000819:agonists*; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism / Q000517:prevention & control*; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use; D016211:Transforming Growth Factor alpha / Q000187:drug effects; D014594:Uterine Neoplasms / Q000378:metabolism / Q000517:prevention & control*
D004965:Estrogen Antagonists; D004967:Estrogens; D010880:Piperidines; D016211:Transforming Growth Factor alpha; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride